Madrigal Pharmaceuticals, Inc.

NASDAQ:MDGL

Biotechnology

Healthcare
$398.08 -0.27%

-$1.33 today

Market cap
$9.25B
Beta
-1.06
P/E (TTM)
-46.9
EPS (TTM)
-$10.66
52W Low $276.67High $615.00

Volume 0.64M

Average 0.31M

MDGL EBITDA

Earnings before interest, taxes, depreciation, and amortization; a proxy for operating profit before non-cash and financing charges.

Madrigal Pharmaceuticals, Inc.NASDAQ: MDGL

EBITDA · Q2 FY2026 · quarter ended Jun 2026

EBITDA remains negative

Q2 FY2026 EBITDA was -$49.62M, compared with -$38.64M a year earlier. Trailing-twelve-month EBITDA was -$292.07M.

Context

  • EBITDA amounted to 27.6% of revenue in FY2025, down 222.3 pp from a year earlier.
  • EBITDA grew in size in 2 of the last 3 fiscal years.
  • FY2025 was the smallest annual figure in the 4 fiscal years shown.

What to watch

Whether EBITDA reaches the consensus estimate from 12 analysts of -$46.9M (+82.3%) for the fiscal year ending Dec 2026, a step up from the +41.2% reported in FY2025.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterJun 2026
-$49.62M+42.4% QoQ
Last fiscal yearDec 2025
-$264.47M+41.2% YoY
LTMJun 2026
-$292.07M-9.5% YoY
EBITDA past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-28.4%+83.4%+111.8 pp
1 year+41.2%+82.3%+41.0 pp
3-year CAGR———
5-year CAGR——
10-year CAGR——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

EBITDA history

USD · from the income statement

Latest · FY2025
(264.47M) USD
Year-over-year change
+41.2%
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

EBITDA vs competitors

How MDGL compares with its peers on the latest reported figures

  • Peers report in different currencies, so EBITDA is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of -9.5% is the 4th highest of 7, against a peer median of -14.9%.
  • EBITDA amounts to 22.7% of revenue for MDGL, versus a peer median of 3219.1%.
MDGL Competitors
EBITDA for MDGL and competitors
Company Period LTM YoY 3-year CAGR% of revenue
SGMTSagimet Biosciences Inc.LTM Mar 2026-$46.14M USD+19.2%——
ALTAltimmune, Inc.LTM Mar 2026-$88.27M USD+2.7%—245200.0%
MAZEMaze Therapeutics, Inc.LTM Mar 2026-$119.51M USD-312.9%—597.6%
IVAInventiva S.A.FY2025-€128.15M EUR+23.0%—2858.6%
NAMSNewAmsterdam Pharma Company N.V.LTM Jun 2026-$254.91M USD-32.5%—3579.7%
MDGLMadrigal Pharmaceuticals, Inc.LTM Jun 2026-$292.07M USD-9.5%—22.7%
VKTXViking Therapeutics, Inc.LTM Jun 2026-$534.34M USD-212.4%——
Peer median (excluding MDGL) —-14.9%—3219.1%

Competitors are the stored peer set for MDGL. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue000180.13M958.4M
Cost of Revenue0006.23M56.15M
Gross Profit000173.9M902.26M
Gross Margin———96.5%94.1%
Research & Development205.16M245.44M272.35M236.72M388.53M
Selling, General & Admin37.32M48.13M108.15M435.06M813.83M
Operating Expenses242.48M293.57M380.5M671.78M1.2B
Depreciation & Amortization405K467K527K1.1M1.51M
EBITDA(241.44M)(290.92M)(360.39M)(450.13M)(264.47M)
EBITDA Margin———-249.9%-27.6%
Operating Income(242.48M)(293.57M)(380.5M)(497.88M)(300.1M)
Operating Margin———-276.4%-31.3%
Interest Income363K2.19M19.58M46.65M37.36M
Interest Expense03.96M12.71M14.67M22.31M
Other Income / Expenses636K(1.78M)6.87M31.98M11.81M
Income Before Tax(241.85M)(295.35M)(373.63M)(465.89M)(288.28M)
Pre-Tax Margin———-258.6%-30.1%
Income Tax Expense00000
Net Income(241.85M)(295.35M)(373.63M)(465.89M)(288.28M)
Net Margin———-258.6%-30.1%
EPS (Basic)(14.63)(17.23)(19.99)(21.90)(12.85)
EPS (Diluted)(14.63)(17.23)(19.99)(21.90)(12.85)
Weighted Avg Shares16.54M17.14M18.69M21.27M22.43M
Weighted Avg Shares (Diluted)16.54M17.14M18.69M21.27M22.43M

Madrigal Pharmaceuticals, Inc.

NASDAQ:MDGL

Intrinsic Alpha fair value

Locked

Current Price

$398.08

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.